- Home
- ANIX vs CRDL Comparison
ANIX vs CRDL Comparison
Compare ANIX & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANIX
- CRDL
- Stock Information
- Founded
- ANIX 1982
- CRDL 2017
- Country
- ANIX United States
- CRDL Canada
- Employees
- ANIX N/A
- CRDL N/A
- Industry
- ANIX Biotechnology: Pharmaceutical Preparations
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ANIX Health Care
- CRDL Health Care
- Exchange
- ANIX Nasdaq
- CRDL Nasdaq
- Market Cap
- ANIX 95.7M
- CRDL 90.4M
- IPO Year
- ANIX 1987
- CRDL N/A
- Fundamental
- Price
- ANIX $4.90
- CRDL $1.07
- Analyst Decision
- ANIX Strong Buy
- CRDL Strong Buy
- Analyst Count
- ANIX 3
- CRDL 2
- Target Price
- ANIX $9.00
- CRDL $9.00
- AVG Volume (30 Days)
- ANIX 216.1K
- CRDL 740.0K
- Earning Date
- ANIX 09-10-2025
- CRDL 11-13-2025
- Dividend Yield
- ANIX N/A
- CRDL N/A
- EPS Growth
- ANIX N/A
- CRDL N/A
- EPS
- ANIX N/A
- CRDL N/A
- Revenue
- ANIX N/A
- CRDL N/A
- Revenue This Year
- ANIX N/A
- CRDL N/A
- Revenue Next Year
- ANIX N/A
- CRDL N/A
- P/E Ratio
- ANIX N/A
- CRDL N/A
- Revenue Growth
- ANIX N/A
- CRDL N/A
- 52 Week Low
- ANIX $2.07
- CRDL $0.77
- 52 Week High
- ANIX $4.49
- CRDL $2.24
- Technical
- Relative Strength Index (RSI)
- ANIX 81.97
- CRDL 46.60
- Support Level
- ANIX $3.21
- CRDL $1.04
- Resistance Level
- ANIX $3.44
- CRDL $1.10
- Average True Range (ATR)
- ANIX 0.21
- CRDL 0.05
- MACD
- ANIX 0.13
- CRDL 0.00
- Stochastic Oscillator
- ANIX 99.48
- CRDL 29.17
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.